MD1716C2 - Use of melatonin for treatment of patients dependent on benzodiazepine - Google Patents

Use of melatonin for treatment of patients dependent on benzodiazepine Download PDF

Info

Publication number
MD1716C2
MD1716C2 MD97-0254A MD970254A MD1716C2 MD 1716 C2 MD1716 C2 MD 1716C2 MD 970254 A MD970254 A MD 970254A MD 1716 C2 MD1716 C2 MD 1716C2
Authority
MD
Moldova
Prior art keywords
benzodiazepine
melatonin
treatment
patient
patients dependent
Prior art date
Application number
MD97-0254A
Other languages
Romanian (ro)
Russian (ru)
Other versions
MD970254A (en
MD1716B2 (en
Inventor
Nava Zisapel
Original Assignee
Neurim Pharmaceuticals (1991) Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/381,535 external-priority patent/US6469044B1/en
Application filed by Neurim Pharmaceuticals (1991) Ltd. filed Critical Neurim Pharmaceuticals (1991) Ltd.
Publication of MD970254A publication Critical patent/MD970254A/en
Publication of MD1716B2 publication Critical patent/MD1716B2/en
Publication of MD1716C2 publication Critical patent/MD1716C2/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404Indoles, e.g. pindolol
    • A61K31/4045Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/20Hypnotics; Sedatives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00General protective or antinoxious agents
    • A61P39/02Antidotes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Addiction (AREA)
  • Psychiatry (AREA)
  • Toxicology (AREA)
  • Anesthesiology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Изобретение относится к применению мелатонина для лечения пациента с полимедикаментозной зависимостью, пациента с симптомами толерантности, зависимости от бензодиазепинового медикамента или пациента с чувствительностью к возникновению состояния спокойствия при применении бензодиазепинового медикамента, одновременно предупреждая появление у него симптомов зависимости, толерантности или избыточного потребления бензодиазепинового медикамента.Ï. ôîðìóëû: 8The invention relates to the use of melatonin for treating a patient with drug dependence, a patient with symptoms of tolerance, dependence on a benzodiazepine medication or a patient with sensitivity to a state of calm when using a benzodiazepine medication, while preventing the symptoms of dependence, tolerance or excessive consumption of a benzodiazepine medication. . Features: 8

MD97-0254A 1995-02-01 1996-01-29 Use of melatonin for treatment of patients dependent on benzodiazepine MD1716C2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US08/381,535 US6469044B1 (en) 1995-02-01 1995-02-01 Method for treating patients suffering from drug dependencies which lead to plasma melationin deficiencies
EP95303853A EP0724878B1 (en) 1995-02-01 1995-06-06 Use of melatonin for treating patients suffering from drug dependencies
PCT/IB1996/000082 WO1996023496A1 (en) 1995-02-01 1996-01-29 Use of melatonin for treating patients suffering from drug addiction

Publications (3)

Publication Number Publication Date
MD970254A MD970254A (en) 1999-05-31
MD1716B2 MD1716B2 (en) 2001-08-31
MD1716C2 true MD1716C2 (en) 2002-02-28

Family

ID=26140195

Family Applications (1)

Application Number Title Priority Date Filing Date
MD97-0254A MD1716C2 (en) 1995-02-01 1996-01-29 Use of melatonin for treatment of patients dependent on benzodiazepine

Country Status (22)

Country Link
JP (1) JP4516159B2 (en)
CN (1) CN1083263C (en)
AT (1) AT408188B (en)
AU (1) AU695366B2 (en)
BG (1) BG62876B1 (en)
BR (1) BR9607169A (en)
CZ (1) CZ291349B6 (en)
DK (1) DK176081B1 (en)
EE (1) EE03384B1 (en)
FI (1) FI119586B (en)
IS (1) IS1980B (en)
LU (1) LU90118B1 (en)
LV (1) LV11940B (en)
MD (1) MD1716C2 (en)
NO (1) NO312814B1 (en)
NZ (1) NZ298878A (en)
PL (1) PL183148B1 (en)
SI (1) SI9620022A (en)
SK (1) SK284521B6 (en)
TR (1) TR199700723T1 (en)
TW (1) TW483757B (en)
WO (1) WO1996023496A1 (en)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TR200201724T2 (en) 2000-01-05 2003-03-21 Neurim Pharmaceuticals (1991) Ltd. Methods and formulas to treat antihypertension and related symptoms
IL149377A (en) * 2002-04-28 2012-10-31 Neurim Pharma 1991 Pharmaceutical formulation comprising melatonin for the potentiation of the effect of hypnotic compounds
US9119846B2 (en) 2003-04-29 2015-09-01 Neurim Pharmaceuticals (1991) Ltd. Method and composition for enhancing cognition in alzheimer's patients
IL155666A (en) 2003-04-29 2013-12-31 Neurim Pharma 1991 Composition for treating insomnia
MX374068B (en) 2012-01-26 2020-07-30 Vanda Pharmaceuticals Inc Treatment of circadian rhythm disorders
US11918557B2 (en) 2012-01-26 2024-03-05 Vanda Pharmaceuticals Inc. Treatment of circadian rhythm disorders
WO2014100292A1 (en) 2012-12-18 2014-06-26 Vanda Pharmaceuticals Inc. Treatment of circadian rhythm disorders
US11090285B2 (en) 2013-11-12 2021-08-17 Vanda Pharmaceuticals Inc Treatment of circadian rhythm disorders
US10376487B2 (en) 2013-11-12 2019-08-13 Vanda Pharmaceuticals Inc. Method of treatment
ES3009413T3 (en) * 2016-10-31 2025-03-26 Neurim Pharma 1991 Melatonin mini-tablets and method of manufacturing the same

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0513702A2 (en) * 1991-05-13 1992-11-19 I.F.L.O. ISTITUTO FARMACOLOGICO LOMBARDO S.A.S. di Giorgio & Aldo Laguzzi & C. Melatonin derivaties for use in the therapy of sleep disorders and in pre-anaesthetic medication
EP0518468A1 (en) * 1991-05-09 1992-12-16 Neurim Pharmaceuticals (1991) Limited Melatonin containing compositions

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0518468A1 (en) * 1991-05-09 1992-12-16 Neurim Pharmaceuticals (1991) Limited Melatonin containing compositions
EP0513702A2 (en) * 1991-05-13 1992-11-19 I.F.L.O. ISTITUTO FARMACOLOGICO LOMBARDO S.A.S. di Giorgio & Aldo Laguzzi & C. Melatonin derivaties for use in the therapy of sleep disorders and in pre-anaesthetic medication

Also Published As

Publication number Publication date
PL183148B1 (en) 2002-05-31
JP4516159B2 (en) 2010-08-04
TW483757B (en) 2002-04-21
JPH10513177A (en) 1998-12-15
FI119586B (en) 2009-01-15
TR199700723T1 (en) 1998-02-21
FI973185A0 (en) 1997-07-31
SK284521B6 (en) 2005-05-05
SK103097A3 (en) 1998-01-14
FI973185L (en) 1997-09-30
LV11940A (en) 1998-01-20
SI9620022A (en) 1998-10-31
DK176081B1 (en) 2006-04-18
WO1996023496A1 (en) 1996-08-08
CN1083263C (en) 2002-04-24
NO312814B1 (en) 2002-07-08
DK89697A (en) 1997-07-30
EE9700166A (en) 1998-02-16
NO973531D0 (en) 1997-07-31
MX9705856A (en) 1998-07-31
MD970254A (en) 1999-05-31
AU4457496A (en) 1996-08-21
CN1172431A (en) 1998-02-04
BG62876B1 (en) 2000-10-31
NZ298878A (en) 1999-05-28
CZ291349B6 (en) 2003-02-12
BR9607169A (en) 1997-11-11
EE03384B1 (en) 2001-04-16
IS4532A (en) 1997-07-25
MD1716B2 (en) 2001-08-31
BG101803A (en) 1998-04-30
NO973531L (en) 1997-09-30
AT408188B (en) 2001-09-25
LV11940B (en) 1998-05-20
CZ240597A3 (en) 1998-01-14
AU695366B2 (en) 1998-08-13
LU90118B1 (en) 1997-11-13
IS1980B (en) 2005-01-14
ATA901396A (en) 2001-02-15
PL321630A1 (en) 1997-12-08

Similar Documents

Publication Publication Date Title
CY2007001I2 (en) MEDICINAL PREPARATION FOR USE IN THE TREATMENT OF DIABETES
ES2165910T3 (en) NASAL AND OCULAR CETAMINE ADMINISTRATION FOR THE TREATMENT OF PAIN AND FOR DETOXIFICATION.
ATE127804T1 (en) PHARMACEUTICAL COMPOUNDS.
PT1025845E (en) THERAPY WITH HYDROMORPHONE
BRPI0009719B8 (en) treatment process
MD1716C2 (en) Use of melatonin for treatment of patients dependent on benzodiazepine
HUP9802091A2 (en) Neural transplantation using pluripotent neuroepithelial cells
DE69617729D1 (en) USE OF ANTIMINERALCORTICOID COMPOUNDS AGAINST THE DRUG DEACTIVATION SYNDROME
DE69318821D1 (en) Catheter for supplying the penis with medication
HUP9802423A2 (en) Combined medical treatment of hyperproliferative diseases
FI874166A7 (en) Use of 2',3'-dideoxycytidin-2'-ene for the treatment of patients infected with retroviruses.
DE3879535D1 (en)
BR0009380A (en) Improved cancer treatment with temozozomide
NO990450L (en) Treatment of mental disorders
PT869785E (en) 4-HYDROXYCUMARIN-3-CARBOXAMIDES FOR THE TREATMENT OF DIABETES MELLITUS NOT INSULINODEPENDENT
NO984651L (en) Use of benzone-offset derivatives for the manufacture of drugs for the treatment of central nervous system diseases
NZ307601A (en) Use of a pharmaceutically acceptable oxalate derivative in the manufacture of a medicament for the treatment of skin conditions
NO984197D0 (en) Procedures for treating autism
ATE207357T1 (en) USE OF COTININE TO RELIEF TOBACCO WITHDRAWAL SYNDROME
NO960545D0 (en) Treatment of adverse effects associated with the administration of extracellular hemoglobin
DE69300037D1 (en) Use of bucillamine in the manufacture of a medicament for the treatment of cystinuria.
KR960003718A (en) Use of Ifenprodil and its Diastereomers for the Preparation of Medicines Useful for the Treatment of Peripheral and Central Neurodegenerative Diseases
SE9000207L (en) MEDICINAL PRODUCTS AND THE USE OF THE SAME
ATE307587T1 (en) USE OF THIAMINES FOR THE PRODUCTION OF A MEDICINAL PRODUCT FOR THE PROPHYLAXIS AND THERAPY OF DIABETIC RETINOPATHY AND DIABETIC NEPHROPATHY
DE3650368D1 (en) Use of Depogen to treat restricted blood circulation.

Legal Events

Date Code Title Description
PD99 Pending application
KA4A Patent for invention lapsed due to non-payment of fees (with right of restoration)
MM4A Patent for invention definitely lapsed due to non-payment of fees